Private Management Group Inc. Sells 98,730 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Private Management Group Inc. lowered its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 6.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,517,438 shares of the company's stock after selling 98,730 shares during the period. Private Management Group Inc. owned about 0.14% of Teva Pharmaceutical Industries worth $15,842,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the company. Blue Trust Inc. grew its holdings in Teva Pharmaceutical Industries by 92.3% during the fourth quarter. Blue Trust Inc. now owns 4,541 shares of the company's stock valued at $46,000 after purchasing an additional 2,180 shares during the period. Signaturefd LLC grew its holdings in Teva Pharmaceutical Industries by 90.8% during the third quarter. Signaturefd LLC now owns 5,032 shares of the company's stock valued at $51,000 after purchasing an additional 2,394 shares during the period. AdvisorNet Financial Inc grew its holdings in Teva Pharmaceutical Industries by 124.7% during the third quarter. AdvisorNet Financial Inc now owns 8,108 shares of the company's stock valued at $83,000 after purchasing an additional 4,500 shares during the period. Desjardins Global Asset Management Inc. lifted its position in shares of Teva Pharmaceutical Industries by 15.2% in the fourth quarter. Desjardins Global Asset Management Inc. now owns 8,123 shares of the company's stock valued at $85,000 after acquiring an additional 1,070 shares in the last quarter. Finally, Schechter Investment Advisors LLC purchased a new position in shares of Teva Pharmaceutical Industries in the fourth quarter valued at about $117,000. Institutional investors own 54.05% of the company's stock.

Analysts Set New Price Targets

TEVA has been the topic of several research analyst reports. Jefferies Financial Group upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating and boosted their price objective for the company from $10.00 to $14.00 in a research report on Tuesday, January 23rd. Barclays boosted their target price on Teva Pharmaceutical Industries from $15.00 to $17.00 and gave the stock an "overweight" rating in a research report on Monday, February 5th. JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from an "underweight" rating to a "neutral" rating and set a $14.00 target price on the stock in a research report on Friday, March 8th. Piper Sandler upgraded Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and boosted their target price for the stock from $12.00 to $19.00 in a research report on Monday, February 12th. Finally, The Goldman Sachs Group boosted their target price on Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the stock a "neutral" rating in a research report on Monday, February 5th. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $13.78.

Teva Pharmaceutical Industries Trading Up 1.0 %

NYSE:TEVA traded up $0.13 during midday trading on Tuesday, hitting $13.01. The stock had a trading volume of 8,981,770 shares, compared to its average volume of 10,621,822. Teva Pharmaceutical Industries Limited has a one year low of $7.09 and a one year high of $14.47. The company has a market capitalization of $14.59 billion, a price-to-earnings ratio of -27.68, a PEG ratio of 1.54 and a beta of 1.05. The stock has a 50-day moving average of $13.50 and a 200 day moving average of $11.33. The company has a quick ratio of 0.69, a current ratio of 1.02 and a debt-to-equity ratio of 2.23.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings data on Wednesday, January 31st. The company reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.25. Teva Pharmaceutical Industries had a positive return on equity of 34.90% and a negative net margin of 3.33%. The company had revenue of $4.46 billion for the quarter, compared to analysts' expectations of $3.97 billion. As a group, sell-side analysts forecast that Teva Pharmaceutical Industries Limited will post 2.28 EPS for the current year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, CAO Amir Weiss sold 31,766 shares of the stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $12.37, for a total transaction of $392,945.42. Following the sale, the chief accounting officer now owns 10,676 shares of the company's stock, valued at approximately $132,062.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CEO Richard D. Francis sold 74,530 shares of the stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $13.15, for a total transaction of $980,069.50. Following the completion of the sale, the chief executive officer now owns 87,125 shares in the company, valued at approximately $1,145,693.75. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CAO Amir Weiss sold 31,766 shares of the stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $12.37, for a total value of $392,945.42. Following the sale, the chief accounting officer now owns 10,676 shares of the company's stock, valued at approximately $132,062.12. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 390,738 shares of company stock valued at $5,132,766. 0.55% of the stock is currently owned by corporate insiders.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.